Cell therapy for diabetic nephropathy: is the future, now?

Area of Science:

• Regenerative Medicine
• Nephrology
• Cardiovascular Research

Background:

• Cell-based therapies aim to enhance angiogenesis and organ function, with over a decade of research in ischemic heart disease.
• Capillary rarefaction is a key factor in diabetic kidney disease pathogenesis.
• The potential of cell therapy in diabetic nephropathy remains underexplored.

Purpose of the Study:

• To investigate the potential of autologous, bone marrow-derived angiogenic cells for treating chronic kidney disease caused by diabetes.
• To evaluate the efficacy and safety of cell-based therapy in the context of diabetic nephropathy.

Main Methods:

• Review of existing research on cell-based therapies for ischemic conditions.
• Analysis of the pathogenetic role of capillary rarefaction in diabetic nephropathy.
• Assessment of safety and efficacy data from animal studies of chronic kidney disease.

Main Results:

• Autologous, bone marrow-derived angiogenic cells possess a favorable safety profile.
• These cells have shown efficacy in preclinical animal models of chronic kidney disease.
• The mechanism of action is believed to involve microvasculature repair.

Conclusions:

• Cell-based therapy, specifically using autologous angiogenic cells, presents a potential therapeutic strategy for advanced diabetic nephropathy.
• The established safety and preclinical efficacy support the initiation of clinical trials.
• Further research is warranted to explore this approach in human patients with diabetic kidney disease.